U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249372) titled 'DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer' on Nov. 18.
Brief Summary: This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer
Intervention:
DRUG: DRP-104
DRP-104 will be administered subcutaneously (subQ) at a dose of 145mg twice a week (BIW) on a continuous schedule. Once the first dose is administered, the second weekly dose is to be administered 3 days after the ...